全文获取类型
收费全文 | 10079篇 |
免费 | 648篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 133篇 |
儿科学 | 424篇 |
妇产科学 | 408篇 |
基础医学 | 1041篇 |
口腔科学 | 149篇 |
临床医学 | 960篇 |
内科学 | 2557篇 |
皮肤病学 | 111篇 |
神经病学 | 925篇 |
特种医学 | 514篇 |
外科学 | 1078篇 |
综合类 | 118篇 |
一般理论 | 13篇 |
预防医学 | 1068篇 |
眼科学 | 173篇 |
药学 | 623篇 |
中国医学 | 2篇 |
肿瘤学 | 458篇 |
出版年
2023年 | 36篇 |
2022年 | 65篇 |
2021年 | 200篇 |
2020年 | 101篇 |
2019年 | 194篇 |
2018年 | 217篇 |
2017年 | 184篇 |
2016年 | 173篇 |
2015年 | 191篇 |
2014年 | 320篇 |
2013年 | 431篇 |
2012年 | 709篇 |
2011年 | 775篇 |
2010年 | 413篇 |
2009年 | 401篇 |
2008年 | 653篇 |
2007年 | 767篇 |
2006年 | 717篇 |
2005年 | 680篇 |
2004年 | 652篇 |
2003年 | 600篇 |
2002年 | 510篇 |
2001年 | 145篇 |
2000年 | 104篇 |
1999年 | 130篇 |
1998年 | 118篇 |
1997年 | 94篇 |
1996年 | 69篇 |
1995年 | 82篇 |
1994年 | 54篇 |
1993年 | 53篇 |
1992年 | 85篇 |
1991年 | 56篇 |
1990年 | 65篇 |
1989年 | 85篇 |
1988年 | 61篇 |
1987年 | 54篇 |
1986年 | 50篇 |
1985年 | 37篇 |
1984年 | 55篇 |
1983年 | 43篇 |
1982年 | 37篇 |
1981年 | 34篇 |
1980年 | 31篇 |
1979年 | 21篇 |
1978年 | 32篇 |
1977年 | 23篇 |
1976年 | 21篇 |
1975年 | 15篇 |
1974年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Patent foramen ovales (PFOs) are common congenital cardiac defects that are more prevalent among patients experiencing cryptogenic stroke than among those with strokes of known origin. Medical treatment for these processes is often considered inadequate, and mechanical closure of the PFO is an attractive, albeit controversial, alternative. Although it is plausible that percutaneous PFO closure will reduce the rate of recurrent stroke in these patients, randomized trials examining the efficacy of devices in this setting have not been completed. In 2007, the Food and Drug Administration convened a meeting of the Circulatory System Devices Panel to discuss the necessity of randomized trials, as well as obstacles to trial enrollment and completion. 相似文献
992.
Israeli RS Rosenberg SJ Saltzstein DR Gottesman JE Goldstein HR Hull GW Tran DN Warsi GM Lacerna LV 《Clinical genitourinary cancer》2007,5(4):271-277
Purpose
The aim of this study was to evaluate the efficacy and safety of zoledronic acid compared with placebo in preventing bone mineral density (BMD) loss and suppressing bone markers when initiated during the first year of androgen deprivation therapy in patients with locally advanced prostate cancer.Patients and Methods
Patients were randomized to receive zoledronic acid 4 mg or placebo intravenously every 3 months. Lumbar spine (LS) and total hip BMD was measured using dual-energy x-ray absorptiometry at baseline and at week 52. N-telopeptide (NTX) and bone-specific alkaline phosphatase (BSAP) were evaluated at baseline and every 12 weeks. Safety assessments were performed throughout the study.Results
Efficacy analyses included 106 patients and 109 patients in the zoledronic acid and placebo groups, respectively. At week 52, the least squares mean BMD percentage differences were 6.7% for LS and 3.7% for total hip (P < 0.0001 for both). In the zoledronic acid group, decreases in NTX (−14% to −28%) and BSAP (−31% to −37%) levels were significant and sustained; changes in NTX levels and LS BMD (r = −0.25; P = 0.04) and in BSAP levels and hip BMD (r = −0.28; P = 0.02) were significantly correlated. Only traumatic fractures were reported for 2 and 3 patients receiving zoledronic acid and placebo, respectively. One patient in each group experienced acute renal failure. Osteonecrosis of the jaw was not reported.Conclusion
Zoledronic acid (4 mg intravenously every 3 months) was safe and effective in preventing bone loss and reducing bone turnover in patients with prostate cancer when initiated during the first year of androgen deprivation therapy; patients with low baseline BMD experienced the greatest benefit. 相似文献993.
Beriwal S Gan GN Heron DE Selvaraj RN Kim H Lalonde R Kelley JL Edwards RP 《International journal of radiation oncology, biology, physics》2007,68(1):166-171
PURPOSE: To assess the early clinical outcomes with concurrent cisplatin and extended-field intensity-modulated radiotherapy (EF-IMRT) for carcinoma of the cervix. METHODS AND MATERIALS: Thirty-six patients with Stage IB2-IVA cervical cancer treated with EF-IMRT were evaluated. The pelvic lymph nodes were involved in 19 patients, and of these 19 patients, 10 also had para-aortic nodal disease. The treatment volume included the cervix, uterus, parametria, presacral space, upper vagina, and pelvic, common iliac, and para-aortic nodes to the superior border of L1. Patients were assessed for acute toxicities according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. All late toxicities were scored with the Radiation Therapy Oncology Group late toxicity score. RESULTS: All patients completed the prescribed course of EF-IMRT. All but 2 patients received brachytherapy. Median length of treatment was 53 days. The median follow-up was 18 months. Acute Grade > or = 3 gastrointestinal, genitourinary, and myelotoxicity were seen in 1, 1, and 10 patients, respectively. Thirty-four patients had complete response to treatment. Of these 34 patients, 11 developed recurrences. The first site of recurrence was in-field in 2 patients (pelvis in 1, pelvis and para-aortic in 1) and distant in 9 patients. The 2-year actuarial locoregional control, disease-free survival, overall survival, and Grade > or = 3 toxicity rates for the entire cohort were 80%, 51%, 65%, and 10%, respectively. CONCLUSION: Extended-field IMRT with concurrent chemotherapy was tolerated well, with acceptable acute and early late toxicities. The locoregional control rate was good, with distant metastases being the predominant mode of failure. We are continuing to accrue a larger number of patients and longer follow-up data to further extend our initial observations with this approach. 相似文献
994.
995.
Sunkara G Sabo R Wang Y He YL Campestrini J Rosenberg M Howard D Dole WP 《Journal of clinical pharmacology》2007,47(9):1152-1158
Vildagliptin is a potent and selective dipeptidyl peptidase IV inhibitor in development for the treatment of type 2 diabetes that improves glycemic control by enhancing alpha- and beta-cell responsiveness to glucose. Two open-label, single-dose, randomized, crossover studies in healthy subjects (ages 18-45 years) investigated the dose proportionality of vildagliptin pharmacokinetics (n = 20) and the effect of food (n = 24) on vildagliptin pharmacokinetics. There was a linear relationship (r(2) = 0.999) between vildagliptin doses of 25, 50, 100, and 200 mg and area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) and maximum plasma concentration (C(max)). Dose proportionality was assessed using a statistical power model [X = alpha x (dose)(beta)]. The 90% confidence intervals of the proportionality coefficient, beta, for AUC(0-infinity) (1.15-1.19) and C(max) (1.04-1.14) indicated that deviations from dose proportionality were small (<7.7%). Doubling of dose led to 2.1- to 2.3-fold increases in AUC(0-infinity) and C(max) but no dose-dependent changes in time to reach C(max) or terminal elimination half-life. Administration of vildagliptin 100 mg following a high-fat meal decreased C(max) by 19% and AUC(0-infinity) by 10%. Vildagliptin displays approximately dose-proportional pharmacokinetics over the 25- to 200-mg dose range, and administration with food has no clinically relevant effect on vildagliptin pharmacokinetics. 相似文献
996.
Lu L Dekhtyar T Masse S Pithawalla R Krishnan P He W Ng T Koev G Stewart K Larson D Bosse T Wagner R Pilot-Matias T Mo H Molla A 《Antiviral research》2007,76(1):93-97
Compound A-837093, a non-nucleoside HCV RNA-dependent RNA polymerase inhibitor, displayed nanomolar potencies against HCV genotypes 1a and 1b replicons. It also exhibited an excellent metabolic profile and achieved high plasma and liver concentrations in animals. In order to characterize the development of resistance to this anti-HCV agent, HCV subgenomic 1b strain N replicon cells were cultured in the presence of A-837093 with G418. Mutations S368A, Y448H, G554D, Y555C, and D559G in the NS5B polymerase gene were identified that led to substantial decreases in the susceptibilities of 1b genotype replicons to the inhibitor A-837093. However, the resistant mutants remained susceptible to HCV protease inhibitor BILN-2061 and alpha interferon as well as to a different class of non-nucleoside HCV polymerase inhibitor. In addition, each single resistant mutation identified significantly reduced the replication capacity of mutant compared to wild-type replicon. These findings provide a strategic guide for the future development of non-nucleoside inhibitors of HCV NS5B polymerase. 相似文献
997.
998.
999.
Jennifer Hollowell Laura Oakley Jennifer J Kurinczuk Peter Brocklehurst Ron Gray 《BMC pregnancy and childbirth》2011,11(1):1-20
Background
Infant mortality has shown a steady decline in recent years but a marked socioeconomic gradient persists. Antenatal care is generally thought to be an effective method of improving pregnancy outcomes, but the effectiveness of specific antenatal care programmes as a means of reducing infant mortality in socioeconomically disadvantaged and vulnerable groups of women has not been rigorously evaluated.Methods
We conducted a systematic review, focusing on evidence from high income countries, to evaluate the effectiveness of alternative models of organising or delivering antenatal care to disadvantaged and vulnerable groups of women vs. standard antenatal care. We searched Medline, Embase, Cinahl, PsychINFO, HMIC, CENTRAL, DARE, MIDIRS and a number of online resources to identify relevant randomised and observational studies. We assessed effects on infant mortality and its major medical causes (preterm birth, congenital anomalies and sudden infant death syndrome (SIDS))Results
We identified 36 distinct eligible studies covering a wide range of interventions, including group antenatal care, clinic-based augmented care, teenage clinics, prenatal substance abuse programmes, home visiting programmes, maternal care coordination and nutritional programmes. Fifteen studies had adequate internal validity: of these, only one was considered to demonstrate a beneficial effect on an outcome of interest. Six interventions were considered 'promising'.Conclusions
There was insufficient evidence of adequate quality to recommend routine implementation of any of the programmes as a means of reducing infant mortality in disadvantaged/vulnerable women. Several interventions merit further more rigorous evaluation. 相似文献1000.